|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A binary logistic regression analyses were conducted to test the association between all four ratings in GAD-7 (anxiety) and PHQ-9 (depression) scales subitems as covariates, and migraine vs no headache as the outcome.
|
28324317 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were 307 psychiatry outpatients with depression; assessed at baseline, 3-, and 6-months on symptom (PHQ-9 and GAD-7), functioning (SF-12) and past-month marijuana use for a substance use intervention trial.
|
28242498 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The resulting groups were characterized with regard to Quality of Life (MacNew), anxiety and depression (GAD-7 and PHQ-9) and resilience (RS-13).
|
28006984 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a cross-sectional study, 23 patients with IPF were evaluated using Montreal Cognitive Assessment (MoCA), an instrument for detecting mild cognitive impairments and were screened for OSA through overnight cardiorespiratory polygraphy and for anxiety and depression with three specific scale (Generalized Anxiety Disorder 7-item scale: GAD-7; the Patient Health Questionnaire: PHQ-9; Hospital Anxiety and Depression Scale: HADS).
|
30707735 |
2019 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a recent association study in depression, which is highly comorbid with panic disorder, GAD1 risk allele associations were restricted to females.
|
22662185 |
2012 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Primary outcomes included the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety.
|
28057609 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, self-rating questionnaires were used to assess somatic symptom severity (PHQ-15), depression severity (PHQ-9) and anxiety severity (GAD-7).
|
28554368 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the third trimester, a second FOBS score, and saliva sample were collected, and the Personal Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) were administered to measure depression and anxiety respectively.
|
31306998 |
2019 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meditation was associated with subjective benefits but no statistically significant effect on depression scores (change in PHQ-9, -3.0±3.9 in the intervention group versus -2.0±4.7 in controls; <i>P</i>=0.45) or anxiety scores (change in GAD-7, -0.9±4.6 versus -0.8±4.8; <i>P</i>=0.91).
|
29025788 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The overall findings suggest that the workbook format was no less effective or acceptable than the validated online format.Significant improvements (avg. improvement; Internet Group vs Workbook Group) in levels of disability (PDI: 16% vs 24%; RMDQ: 12% vs 15%), anxiety (GAD-7: 36% vs 26%), and depression (PHQ-9: 36% vs 36%) were observed in both groups immediately posttreatment.
|
28394850 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hearing performance was assessed with Freiburg monosyllabic test and Oldenburg inventory (OI); the health-related quality of life was measured with Nijmegen Cochlear Implantation Questionnaire (NCIQ); depressive symptoms with General Depression Scale (ADS-L); stress with Perceived Stress Questionnaire (PSQ) and anxiety with General Anxiety Disorder-7 (GAD-7).
|
30870379 |
2019 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PWE from rural West China were evaluated for depression and anxiety with the Neurological Disorders Depression Inventory for Epilepsy (C-NDDI-E; Chinese version) and the Generalized Anxiety Disorder-7 (GAD-7; Chinese version).
|
30125939 |
2018 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical diagnoses, the Patient Health Questionnaire depression (PHQ-9) and somatization modules (PHQ-15), the Generalized Anxiety Disorder Scale (GAD-7), the Liebowitz Social Anxiety Scale (LSAS), and the Short-Form-12 Health Survey (SF-12) were used in the clinical sample.
|
29178857 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were also screened for depression using the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) and the Center for Epidemiologic Studies Depression Scale (CES-D) and for anxiety using the Generalized Anxiety Disorder-7 (GAD-7) scale.
|
31181426 |
2019 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Associations between non-disclosure and the following factors were established using modified Poisson regression with adjustment for socio-demographic factors (gender, age group, ethnicity), HIV-related factors (time since HIV diagnosis, ART status), and clinic: low social support (score ≤ 12 on modified Duke-UNC FSSQ); depression and anxiety symptoms (≥10 on PHQ-9 and GAD-7 respectively); self-reported ART non-adherence in past 2 weeks/3 months; VL non-suppression (clinic-recorded VL > 50 copies/mL among those who started ART ≥ 6 months ago).
|
27586375 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary outcome measures were assessed with the Generalized Anxiety Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8), Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-1).
|
29351138 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
They completed the Centre for Epidemiologic Studies Depression Scale (CES-D) and the General Anxiety Disorder Scale (GAD-7) to measure whether they experience depression and/or anxiety symptoms.
|
29543833 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
PSYGENET |
We also found suggestive associations in women for GAD1, GRIA3, and BDNF with depression accompanied by fatigue, and for CRHR1 with depression accompanied by early morning awakenings.
|
19548263 |
2010 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Respectively 21.4% and 7.8% of the participants had depression and clinical symptoms of GAD.
|
30550597 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in DEMS correlated with changes in both PHQ-8 and GAD-7 in the subgroup of patients without prior depression or anxiety diagnosis (ρ = 0.6, P = 0.002; ρ = 0.4, P = 0.02).
|
30950896 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depression was more commonly studied (ranged from 1%-30%).Prevalence of GAD ranged from 1%-26%.
|
29966886 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the 336 usable responses, 16.1% scored 10 or greater on the PHQ-8 consistent with current depression while 17.3% scored 10 or greater on the GAD-7 consistent with current anxiety.
|
30637564 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
PSYGENET |
As a consequence broader entities such as depression-GAD spectrum, panic-phobias spectrum and OCD spectrum including eating disorders and pathological gambling are taken into consideration; (c) Diagnostic categories use thresholds to delimitate a border with normals.This creates "subthreshold" conditions.
|
18344044 |
2008 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PHQ-9 and GAD-7 were determined to be potential screening tools to aid Chinese medical workers in recognizing depression and anxiety in nonpsychiatric departments.
|
30762438 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
FMR1 gene polymorphisms, dopaminergic (DAT, DRD, COMT), serotonin (5-HTTLPR, HTR1A, HTR2A), interleukins, MCR1, HCN (potassium channel), neurorregulinas, GABAergic (GABA, GAD, DBI) DBI, GABA (Gabra) receptors and GAD genes (GAD1, GAD2) appear to contribute to generate condition of depression or anxiety like.
|
25106036 |
2014 |